Search Results

Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Relievant Medsystems Inc.

Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive agreement to acquire Relievant Medsystems, Inc., a privately held medical technology company.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic low back pain, announced that Anthem Blue Cross and Blue Shield has established favorable coverage for the Intracept® Procedure.

Relievant Medsystems today announced the release of next-generation Intracept ® Access Instruments.

Relievant Medsystems announced the publication of a pooled analysis from three prospective clinical trials that demonstrates the impact of the company’s Intracept® Procedure on significantly reducing the long-term utilization of additional treatments for low back pain.

Relievant Medsystems announced the presentation of four-year pooled results from two prospective clinical trials that further demonstrate the safety, effectiveness and long-term durability of the Intracept® Procedure for patients with vertebrogenic pain.

Relievant Medsystems announced the publication of three-year pooled results from two prospective clinical trials that further validate the safety, effectiveness and long-term durability of the Intracept® Procedure for patients with vertebrogenic pain.

Relievant Medsystems, a company dedicated to transforming the diagnosis and treatment of vertebrogenic pain, a type of chronic low back pain (CLBP), today announced that Palmetto GBA has published a final Local Coverage Determination (LCD) for basivertebral nerve (BVN) ablation that expands access to more than 5 million covered lives.

Credence MedSystems announced that it has successfully completed Factory Acceptance Testing for production of its Companion® injection device platform on the Company’s new Clinical Assembly Line.

Relievant Medsystems announced that basivertebral nerve ablation received a Grade A Quality of Evidence Ranking with High Level of Certainty Regarding Net Benefit in the American Society of Pain & Neuroscience Evidence-Based Clinical Guideline of Interventional Treatments for Low Back Pain.